| Q59087022 | A human proinsulin variant at arginine 65 |
| Q34612016 | A mutation in the B chain coding region is associated with impaired proinsulin conversion in a family with hyperproinsulinemia |
| Q24299942 | A structurally abnormal insulin causing human diabetes |
| Q34345376 | A superactive insulin: [B10-aspartic acid]insulin(human). |
| Q34558557 | Biochemical and clinical implications of proinsulin conversion intermediates |
| Q40173379 | Biologic and Clinical Importance of Proinsulin |
| Q36415779 | Carboxypeptidase E and Secretogranin III Coordinately Facilitate Efficient Sorting of Proopiomelanocortin to the Regulated Secretory Pathway in AtT20 Cells |
| Q37626633 | Clinical Significance of Circulating Proinsulin and C-Peptide |
| Q38672444 | DNA polymorphisms of the human insulin and receptor genes in type 2 diabetes mellitus. |
| Q34521125 | Diabetes due to secretion of a structurally abnormal insulin (insulin Wakayama). Clinical and functional characteristics of [LeuA3] insulin |
| Q37052177 | Dominant inheritance of large molecular weight immunoreactive glucagon |
| Q47335533 | Dominant inheritance of large molecular weight species of glucagon |
| Q40266585 | Etiologies of diabetes mellitus. |
| Q31114544 | Expression and secretion of human proinsulin-B10 from mouse salivary glands: implications for the treatment of type I diabetes mellitus |
| Q34605349 | Familial hyperproinsulinemia. Two cohorts secreting indistinguishable type II intermediates of proinsulin conversion |
| Q37333762 | Familial hyperproinsulinemia: partial characterization of circulating proinsulin-like material |
| Q39764306 | Genetic polymorphisms related to glucose and triglyceride intolerance |
| Q39821195 | Glucagon: Secretion and Actions |
| Q27013618 | INS-gene mutations: from genetics and beta cell biology to clinical disease |
| Q39572640 | Indirect two-site immunoradiometric assay of rat and mouse proinsulin |
| Q40154778 | Insulin Sensitivity and Responsiveness in Vitro and in Vivo |
| Q54117527 | Insulin action and insulin resistance: diseases involving defects in insulin receptors, signal transduction, and the glucose transport effector system. |
| Q54515296 | Insulin action and resistance in obesity and noninsulin-dependent type II diabetes mellitus. |
| Q40325465 | Insulin biosynthesis and diabetes mellitus |
| Q40246537 | Insulin resistance in non-insulin-dependent, type II diabetes mellitus |
| Q51636959 | Mechanisms of insulin resistance in non-insulin-dependent (type II) diabetes. |
| Q36003395 | New roles of carboxypeptidase E in endocrine and neural function and cancer |
| Q40481212 | Parental imprinting effect at the INS-IGF2 diabetes susceptibility locus |
| Q33866630 | Partial diversion of a mutant proinsulin (B10 aspartic acid) from the regulated to the constitutive secretory pathway in transfected AtT-20 cells |
| Q70250804 | Pathogenetic mechanisms of hereditary diabetes mellitus |
| Q50828445 | Peripheral Metabolism of Hormones: Clinical Implications |
| Q40117694 | Plasma proinsulin, C-peptide and insulin in diagnostic suppression tests for insulinomas |
| Q40919434 | Posttranslational cleavage of proinsulin is blocked by a point mutation in familial hyperproinsulinemia |
| Q39614960 | Proinsulin and C-Peptide in Diabetes |
| Q39860624 | Proinsulin and C-peptide: A review |
| Q39578344 | Role of insulin resistance in the pathogenesis of type 2 (non-insulin-dependent) diabetes mellitus |
| Q36597501 | Seven mutations in the human insulin gene linked to permanent neonatal/infancy-onset diabetes mellitus |
| Q67370088 | The genetics of diabetes mellitus |
| Q56610985 | The insulin gene is located on chromosome 11 in humans |
| Q37891941 | The syndromes of primary hormone resistance |
| Q35796032 | Topographic abnormalities of proinsulin to insulin conversion in functioning human insulinomas. Comparison of immunoelectron microscopic and clinical data |